Search
for
Sort by
Research 30 of 1000+
- Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
- Using artificial intelligence to compute Severity of Alopecia Tool scores
- Using qualitative methods to establish the clinically meaningful threshold for treatment success for the Severity of Alopecia Tool (SALT) score
- 125: Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study
- Two‐dimensional planimetry for alopecia areata severity evaluation compared with severity of alopecia tool: A pilot study
- 15 Evaluation of several hematological and inflammatory parameters in patients with alopecia areata and their correlation with disease severity
- 701 Rethinking alopecia scores: Correlating measures of hair loss with established photographic scoring systems
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Diagnosis and severity assessment
- Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Reply to: “Serum vitamin D level and disease severity of alopecia areata: A meta-regression analysis”
- SALT Score Cards: Facilitating SALT Score Calculation in Alopecia Areata
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- Estimation of Claudin 3 in the Sreum of Alopecia Areata Patients and Its Association with Disease Severity
- 1315 An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity
- Quantitative evaluation of carcinosin as an individualized remedy in pediatric alopecia areata using salt score and ludwig hair loss scales: A case report
- Serum level of retinol-binding protein 4 in alopecia areata: relation with recurrence and severity
- STRIAA (Severity TRichoscopy Index Alopecia Areata): Validation of a Novel Trichoscopic Tool for Evaluation of Alopecia Areata
- Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
- Alopecia Areata Treated with Homoeopathic Preparation of Phosphorus: Two Evidence-Based Case Reports
- Alopesia universalis pada anak yang berespon baik dengan terapi kombinasi: sebuah laporan kasus
- Reply to “Vitamin D status in scarring and nonscarring alopecia”
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience